NeuroOne Medical Technologies (NASDAQ:NMTC) Upgraded at Zacks Research

Zacks Research upgraded shares of NeuroOne Medical Technologies (NASDAQ:NMTC) from a hold rating to a strong-buy rating in a report published on Monday,Zacks.com reports.

A number of other research firms have also recently issued reports on NMTC. Wall Street Zen raised NeuroOne Medical Technologies to a “hold” rating in a research report on Friday, October 3rd. Maxim Group started coverage on NeuroOne Medical Technologies in a research note on Tuesday, September 9th. They set a “buy” rating and a $3.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $2.23.

NeuroOne Medical Technologies Stock Performance

NMTC stock opened at $0.90 on Monday. The firm has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $0.79. NeuroOne Medical Technologies has a 52 week low of $0.40 and a 52 week high of $1.39. The stock has a market cap of $45.36 million, a P/E ratio of -11.25 and a beta of 0.70.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, December 16th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. NeuroOne Medical Technologies had a negative net margin of 29.81% and a negative return on equity of 74.69%. The company had revenue of $2.74 million during the quarter, compared to the consensus estimate of $2.47 million. During the same quarter in the prior year, the firm earned ($0.46) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Focus Financial Network Inc. acquired a new stake in NeuroOne Medical Technologies in the 3rd quarter worth approximately $31,000. Warberg Asset Management LLC bought a new position in shares of NeuroOne Medical Technologies in the second quarter valued at approximately $27,000. Susquehanna International Group LLP acquired a new stake in shares of NeuroOne Medical Technologies in the third quarter worth $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies in the second quarter worth $51,000. Finally, Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies in the 1st quarter valued at $84,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.